IIC
AZN icon

Integrated Investment Consultants’s AstraZeneca AZN Stock Holding History

Integrated Investment Consultants’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,767
Closed -$260K – 329
2025
Q1 		$260K Sell
1,767
-250
-12% -$36.2K 0.05% 272
2024
Q4 		$264K Sell
2,017
-142
-7% -$19.9K 0.05% 251
2024
Q3 		$336K Buy
+2,159
New +$349K 0.07% 212
2023
Q2 		– Sell
-4,428
Closed -$615K – 279
2023
Q1 		$615K Sell
4,428
-609
-12% -$81.9K 0.19% 83
2022
Q4 		$683K Buy
5,037
+74
+1% +$9.28K 0.23% 66
2022
Q3 		$545K Sell
4,963
-130
-3% -$16.5K 0.22% 72
2022
Q2 		$672K Sell
5,093
-2,310
-31% -$303K 0.24% 63
2022
Q1 		$982K Sell
7,403
-964
-12% -$116K 0.27% 59
2021
Q4 		$976K Hold
8,367
– – 0.26% 62
2021
Q3 		$1.01M Buy
8,367
+125
+2% +$14.6K 0.29% 56
2021
Q2 		$988K Buy
8,242
+3,530
+75% +$387K 0.29% 56
2021
Q1 		$468K Sell
4,712
-560
-11% -$56.3K 0.16% 118
2020
Q4 		$527K Buy
5,272
+450
+9% +$47.7K 0.2% 92
2020
Q3 		$528K Buy
4,822
+493
+11% +$54.8K 0.25% 78
2020
Q2 		$458K Sell
4,329
-790
-15% -$81.6K 0.22% 76
2020
Q1 		$457K Buy
5,119
+1,046
+26% +$98.5K 0.27% 67
2019
Q4 		$406K Buy
4,073
+746
+22% +$70.2K 0.17% 92
2019
Q3 		$296K Buy
+3,327
New +$288K 0.15% 104
2018
Q2 		– Sell
-202
Closed -$14K – 210
2018
Q1 		$14K Buy
+202
New +$14K 0.01% 584
2016
Q4 		– Sell
-1,477
Closed -$91K – 579
2016
Q3 		$91K Sell
1,477
-901
-38% -$58.9K 0.05% 287
2016
Q2 		$144K Buy
2,378
+137
+6% +$7.96K 0.08% 187
2016
Q1 		$132K Buy
+2,241
New +$135K 0.08% 175

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Integrated Investment Consultants's AZN Position: Q2 2025 in Review

Integrated Investment Consultants sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 1,767 shares — an estimated $260K sold.

Integrated Investment Consultants first reported a position in AZN in Q1 2016 and held it in 22 quarters. The position peaked at $1.01M in Q3 2021. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

  • Integrated Investment Consultants reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
  • Integrated Investment Consultants sold 1,767 AstraZeneca shares in Q2 2025, an estimated $260K.
  • Integrated Investment Consultants first reported a position in AstraZeneca in Q1 2016 and held it in 22 quarters.
  • Integrated Investment Consultants's AstraZeneca position peaked at $1.01M in Q3 2021.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Integrated Investment Consultants's 13F filing for Q2 2025, filed 14 Aug 2025.